AbbVie has a lot of things going for it, but the biotech faces some major risks.
These three big pharma stocks offer compelling valuations and long-term growth trajectories.
Investors should benefit from these biotechs' cholesterol drugs.
The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.
Over their lifetimes, these top-selling medicines have generated between $35 billion and $148 billion in sales.
AbbVie, Amgen, and Gilead Sciences make the list of top biotech dividend stocks. But which is the best of all?
Goldman Sachs has "conviction" this is the drug stock to buy.
AbbVie executives answered questions about the biotech's future at the Cowen healthcare conference.
Which high-growth cloud play is a better buy at current prices?
If you're new to biotech investing, these are three companies you need to know.